Abivax: appointment of board observer

(CercleFinance.com) - Abivax announces the appointment of Mark Stenhouse as board observer and advisor to the company, to which he will bring over 30 years' experience in the biopharmaceutical industry.


Mark Stenhouse was most recently COO of Prometheus Biosciences, a biotech company specializing in gastrointestinal diseases, which was acquired by Merck for $10.8 billion in 2023.

Prior to joining Prometheus, he spent over 25 years at AbbVie, most recently as Vice President of Immunology in the USA. In this capacity, he oversaw Humira's sales and marketing teams in the country.

Copyright (c) 2024 CercleFinance.com. All rights reserved.